复发/难治性多发性骨髓瘤的III期TOURMALINE-MM1研究中伊沙佐米-来那度胺-地塞米松与安慰剂-来那度胺-地塞米松的患者报告健康相关生活质量
III期随机双盲安慰剂对照TOURMALINE-MM1研究比较伊沙佐米联合来那度胺地塞米松(IRd)与安慰剂-Rd方案在复发/难治性多发性骨髓瘤患者中的疗效与患者报告健康相关生活质量(HRQoL)。IRd组中位无进展生存期显著延长(20.6 vs 14.7个月,风险比0.74,P=0.01),额外毒性有限。两组QLQ-C30总体健康状况/生活质量及功能领域评分自基线维持,组间无统计学显著差异。
要点
- IRd组中位无进展生存期20.6个月,安慰剂-Rd组14.7个月,风险比0.74,P=0.01。
- 两组QLQ-C30总体健康状况/生活质量评分自基线维持,组间无统计学显著差异。
- IRd组身体、情绪和社会功能领域评分自基线维持,早期时间点平均变化略高于安慰剂-Rd组。
核心结论
- 在TOURMALINE-MM1研究中,伊沙佐米加入来那度胺地塞米松方案显著改善疗效,同时健康相关生活质量得以维持,反映了IRd相比安慰剂-Rd的额外毒性有限,并支持长期IRd给药的可行性。
研究设计与样本
- III期随机双盲安慰剂对照研究,纳入既往接受1-3线治疗的复发/难治性多发性骨髓瘤患者,比较伊沙佐米联合来那度胺地塞米松(IRd)与安慰剂-来那度胺地塞米松(安慰剂-Rd)。
- 患者报告健康相关生活质量为次要终点,采用EORTC QLQ-C30和QLQ-MY20量表在筛查、第1和第2周期开始、每两个周期、治疗结束以及每4周直至疾病进展时完成评估。
主要发现
- IRd组中位无进展生存期20.6个月 vs 安慰剂-Rd组14.7个月,风险比0.74,P=0.01。
- IRd组和安慰剂-Rd组的中位随访时间分别为23.3个月和22.9个月。
- 两组QLQ-C30总体健康状况/生活质量平均评分自基线在治疗过程中维持,组间无统计学显著差异。
- EORTC QLQ-C30功能领域评分总体自基线维持;身体、情绪和社会功能领域在IRd组与安慰剂-Rd组均维持,IRd组在较早时间点的平均自基线变化评分略高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOURMALINE-MM1 is a phase III, randomized, double-blind, placebo-controlled study of ixazomib plus lenalidomide and dexamethasone (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma following 1-3 prior lines of therapy. The study met its primary endpoint, demonstrating significantly longer progression-free survival (PFS) in the IRd arm versus placebo-Rd arm (median 20.6 vs 14.7 months, hazard ratio 0.74, P = .01), with limited additional toxicity. Patient-reported health-related quality of life (HRQoL) was a secondary endpoint of TOURMALINE-MM1. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) and Multiple Myeloma Module 20 (QLQ-MY20) were completed at screening, the start of cycles 1 and 2, every other cycle, the end of treatment, and every 4 weeks until progression. Over median follow-up of 23.3 and 22.9 months in the IRd and placebo-Rd arms, mean QLQ-C30 global health status (GHS)/QoL scores were maintained from baseline over the course of treatment in both groups, with no statistically significant differences between groups. EORTC QLQ-C30 function domain scores were also generally maintained from baseline; similarly, physical, emotional, and social function domains were maintained with IRd versus placebo-Rd, with slightly higher mean change from baseline scores at earlier time points with IRd. Findings from this double-blind study demonstrate that addition of ixazomib to Rd significantly improved efficacy while HRQoL was maintained, reflecting the limited additional toxicity seen with IRd versus placebo-Rd, and support the feasibility of long-term IRd administration.
引用
- Leleu X, Masszi T, Bahlis NJ, et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol. 2018. PMID: 29726031. doi:10.1002/ajh.25134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。